Selected research
Industry Research
Rifaximin Capsules Industry Research Report 2026
Market perspective
The global Rifaximin Capsules market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Rifaximin Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Rifaximin Capsules is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Rifaximin Capsules is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Rifaximin Capsules include Aden Healthcare, Alfasigma SpA, Estrellas Life Sciences Private Limited, Hainan Hailing Chemical Pharmaceutical Co., Ltd., Hainan Sanye Pharmaceutical Factory Co., Ltd., Shanghai Xinya Pharmaceutical Minhang Co., Ltd. and Southwest Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Rifaximin Capsules market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Rifaximin Capsules Market by Company
Aden Healthcare
Alfasigma SpA
Estrellas Life Sciences Private Limited
Hainan Hailing Chemical Pharmaceutical Co., Ltd.
Hainan Sanye Pharmaceutical Factory Co., Ltd.
Shanghai Xinya Pharmaceutical Minhang Co., Ltd.
Southwest Pharmaceutical Co., Ltd.
Rifaximin Capsules Segment by Type
0.1g
0.2g
Rifaximin Capsules Segment by Application
Hospital
Clinic
Other
Rifaximin Capsules Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rifaximin Capsules market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rifaximin Capsules and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rifaximin Capsules.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Rifaximin Capsules manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Rifaximin Capsules by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Rifaximin Capsules in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 0.1g
- 0.2g
Applications
- Hospital
- Clinic
- Other
Companies covered
- Aden Healthcare
- Alfasigma SpA
- Estrellas Life Sciences Private Limited
- Hainan Hailing Chemical Pharmaceutical Co., Ltd.
- Hainan Sanye Pharmaceutical Factory Co., Ltd.
- Shanghai Xinya Pharmaceutical Minhang Co., Ltd.
- Southwest Pharmaceutical Co., Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Rifaximin Capsules Market Size (2021-2032)
- 2.2.2 Global Rifaximin Capsules Sales (2021-2032)
- 2.2.3 Global Rifaximin Capsules Market Average Price (2021-2032)
- 2.3 Rifaximin Capsules by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 0.1g
- 2.3.3 0.2g
- 2.4 Rifaximin Capsules by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Rifaximin Capsules Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Rifaximin Capsules Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Rifaximin Capsules Revenue of Manufacturers (2021-2026)
- 3.4 Global Rifaximin Capsules Average Price by Manufacturers (2021-2026)
- 3.5 Global Rifaximin Capsules Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Rifaximin Capsules, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Rifaximin Capsules, Product Type & Application
- 3.8 Global Manufacturers of Rifaximin Capsules, Established Date
- 3.9 Global Rifaximin Capsules Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Aden Healthcare
- 4.1.1 Aden Healthcare Company Information
- 4.1.2 Aden Healthcare Business Overview
- 4.1.3 Aden Healthcare Rifaximin Capsules Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Aden Healthcare Rifaximin Capsules Product Portfolio
- 4.1.5 Aden Healthcare Recent Developments
- 4.2 Alfasigma SpA
- 4.2.1 Alfasigma SpA Company Information
- 4.2.2 Alfasigma SpA Business Overview
- 4.2.3 Alfasigma SpA Rifaximin Capsules Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Alfasigma SpA Rifaximin Capsules Product Portfolio
- 4.2.5 Alfasigma SpA Recent Developments
- 4.3 Estrellas Life Sciences Private Limited
- 4.3.1 Estrellas Life Sciences Private Limited Company Information
- 4.3.2 Estrellas Life Sciences Private Limited Business Overview
- 4.3.3 Estrellas Life Sciences Private Limited Rifaximin Capsules Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Estrellas Life Sciences Private Limited Rifaximin Capsules Product Portfolio
- 4.3.5 Estrellas Life Sciences Private Limited Recent Developments
- 4.4 Hainan Hailing Chemical Pharmaceutical Co., Ltd.
- 4.4.1 Hainan Hailing Chemical Pharmaceutical Co., Ltd. Company Information
- 4.4.2 Hainan Hailing Chemical Pharmaceutical Co., Ltd. Business Overview
- 4.4.3 Hainan Hailing Chemical Pharmaceutical Co., Ltd. Rifaximin Capsules Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hainan Hailing Chemical Pharmaceutical Co., Ltd. Rifaximin Capsules Product Portfolio
- 4.4.5 Hainan Hailing Chemical Pharmaceutical Co., Ltd. Recent Developments
- 4.5 Hainan Sanye Pharmaceutical Factory Co., Ltd.
- 4.5.1 Hainan Sanye Pharmaceutical Factory Co., Ltd. Company Information
- 4.5.2 Hainan Sanye Pharmaceutical Factory Co., Ltd. Business Overview
- 4.5.3 Hainan Sanye Pharmaceutical Factory Co., Ltd. Rifaximin Capsules Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hainan Sanye Pharmaceutical Factory Co., Ltd. Rifaximin Capsules Product Portfolio
- 4.5.5 Hainan Sanye Pharmaceutical Factory Co., Ltd. Recent Developments
- 4.6 Shanghai Xinya Pharmaceutical Minhang Co., Ltd.
- 4.6.1 Shanghai Xinya Pharmaceutical Minhang Co., Ltd. Company Information
- 4.6.2 Shanghai Xinya Pharmaceutical Minhang Co., Ltd. Business Overview
- 4.6.3 Shanghai Xinya Pharmaceutical Minhang Co., Ltd. Rifaximin Capsules Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Shanghai Xinya Pharmaceutical Minhang Co., Ltd. Rifaximin Capsules Product Portfolio
- 4.6.5 Shanghai Xinya Pharmaceutical Minhang Co., Ltd. Recent Developments
- 4.7 Southwest Pharmaceutical Co., Ltd.
- 4.7.1 Southwest Pharmaceutical Co., Ltd. Company Information
- 4.7.2 Southwest Pharmaceutical Co., Ltd. Business Overview
- 4.7.3 Southwest Pharmaceutical Co., Ltd. Rifaximin Capsules Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Southwest Pharmaceutical Co., Ltd. Rifaximin Capsules Product Portfolio
- 4.7.5 Southwest Pharmaceutical Co., Ltd. Recent Developments
5 Global Rifaximin Capsules Market Scenario by Region
- 5.1 Global Rifaximin Capsules Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Rifaximin Capsules Sales by Region: 2021-2032
- 5.2.1 Global Rifaximin Capsules Sales by Region: 2021-2026
- 5.2.2 Global Rifaximin Capsules Sales by Region: 2027-2032
- 5.3 Global Rifaximin Capsules Revenue by Region: 2021-2032
- 5.3.1 Global Rifaximin Capsules Revenue by Region: 2021-2026
- 5.3.2 Global Rifaximin Capsules Revenue by Region: 2027-2032
- 5.4 North America Rifaximin Capsules Market Facts & Figures by Country
- 5.4.1 North America Rifaximin Capsules Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Rifaximin Capsules Sales by Country (2021-2032)
- 5.4.3 North America Rifaximin Capsules Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Rifaximin Capsules Market Facts & Figures by Country
- 5.5.1 Europe Rifaximin Capsules Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Rifaximin Capsules Sales by Country (2021-2032)
- 5.5.3 Europe Rifaximin Capsules Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Rifaximin Capsules Market Facts & Figures by Country
- 5.6.1 Asia Pacific Rifaximin Capsules Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Rifaximin Capsules Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Rifaximin Capsules Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Rifaximin Capsules Market Facts & Figures by Country
- 5.7.1 South America Rifaximin Capsules Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Rifaximin Capsules Sales by Country (2021-2032)
- 5.7.3 South America Rifaximin Capsules Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Rifaximin Capsules Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Rifaximin Capsules Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Rifaximin Capsules Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Rifaximin Capsules Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Rifaximin Capsules Sales by Type (2021-2032)
- 6.1.1 Global Rifaximin Capsules Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Rifaximin Capsules Sales Market Share by Type (2021-2032)
- 6.2 Global Rifaximin Capsules Revenue by Type (2021-2032)
- 6.2.1 Global Rifaximin Capsules Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Rifaximin Capsules Revenue Market Share by Type (2021-2032)
- 6.3 Global Rifaximin Capsules Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Rifaximin Capsules Sales by Application (2021-2032)
- 7.1.1 Global Rifaximin Capsules Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Rifaximin Capsules Sales Market Share by Application (2021-2032)
- 7.2 Global Rifaximin Capsules Revenue by Application (2021-2032)
- 7.2.1 Global Rifaximin Capsules Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Rifaximin Capsules Revenue Market Share by Application (2021-2032)
- 7.3 Global Rifaximin Capsules Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Rifaximin Capsules Value Chain Analysis
- 8.1.1 Rifaximin Capsules Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Rifaximin Capsules Production Mode & Process
- 8.2 Rifaximin Capsules Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Rifaximin Capsules Distributors
- 8.2.3 Rifaximin Capsules Customers
9 Global Rifaximin Capsules Analyzing Market Dynamics
- 9.1 Rifaximin Capsules Industry Trends
- 9.2 Rifaximin Capsules Industry Drivers
- 9.3 Rifaximin Capsules Industry Opportunities and Challenges
- 9.4 Rifaximin Capsules Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst